INHIBIKASE THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE AND AWARD AGREEMENTNotice And • March 8th, 2022 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), pursuant to its 2020 Equity Incentive Plan (the “Plan”), hereby grants to the individual listed below (“Participant”) an option to purchase the number of Shares set forth below (the “Option”). The Option described in this Stock Option Grant Notice (the “Grant Notice”) is subject to the terms and conditions set forth in the Award Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, capitalized terms used in this Grant Notice and the Agreement will have the meanings defined in the Plan.
Amendment 1 Employment Agreement for Milton H. Werner, PhD Chief Executive Officer and PresidentInhibikase Therapeutics, Inc. • March 8th, 2022 • Biological products, (no disgnostic substances)
Pursuant to the Compensation Committee recommendations of February 24, 2022 to the Board of Directors of Inhibikase Therapeutics, Inc. (the “Company”), the following modification is made to the Employment Agreement of Dr. Milton Werner dated December 28, 2020:
Amendment 1 Employment Agreement for Joseph Frattaroli Chief Financial OfficerEmployment Agreement • March 8th, 2022 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances)
Pursuant to the Compensation Committee recommendations of February 24, 2022 to the Board of Directors of Inhibikase Therapeutics, Inc., the following modification is made to the Employment Agreement of Joseph Frattaroli dated October 24, 2018:
